Page 3 - Rob Etherington News Today

Published: May 17, 2021 International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease Clene anticipates the expansion of disease indications for CNM-Au8 beyond amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis SALT LAKE CITY, May 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its who...

Clene Reports First Quarter 2021 Operating and Financial Highlights May 11, 2021 07:00 ET | Source: Clene Inc. Clene Inc. Salt Lake City, UNITED STATES Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients Awarded Michael J. Fox Foundation (MJFF) grant to accelerate development of CNM-Au8 as a treatment for Parkinson�...

NORTH EAST — Imagine a future where such diseases as Multiple Sclerosis, Lou Gehrig’s Disease and Parkinson’s Disease can be controlled or stopped altogether. It’s more than imagination at Clene Nanomedicine, Inc. in North East where Mark Mortenson and Rob Etherington are leading the charge against these and other insidious degenerative diseases. Mortenson is the founder and CSO and works out of the manufacturing and research and development headquarters on Principio Parkway...

4.5 (32) Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent and Trademark Office (USPTO) to indicate an examiner has determined an application merits the requested patent being issued. According to Clene, its gold nanocrystal...

Home / Top News / Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis Resulting patent to cover methods of using Clene’s lead candidate CNM-Au8, now in Phase 2 and 3 trials for Multiple Sclerosis (MS) and Amyotrophic lateral sclerosis (ALS) Latest patent all...

Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases. Clene is developing a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of ...

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020 Clinical pipeline includes an ongoing Phase 3 study in amyotrophic lateral sclerosis (ALS) and four concurrent Phase 2 studies in ALS, multiple sclerosis and Parkinson’s disease Proceeds from the transaction totaled approximately $31.9 million,...

Share: SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metab...